Hanni Stoklosa, MD, MPH, Marti MacGibbon, CADC-II, ACRPS, and Joseph Stoklosa, MD
Clinicians diagnosing and treating potentially trafficked patients with co-occurring addiction and mental illness should guard against expressing negative biases.
AMA J Ethics. 2017;19(1):23-24. doi:
10.1001/journalofethics.2017.19.1.ecas3-1701.
Jennifer D. Byrne, LCSW, CADC, Katie S. Clancy, MSW, and Isabell Ciszewski, LCSW
Social work perspectives on whether prescribers should authorize opioid refills emphasize the importance of multidisciplinary approaches to patient self-determination.
AMA J Ethics. 2020;22(8):E658-663. doi:
10.1001/amajethics.2020.658.
Considering chronic opioid use when planning elective surgery would likely enhance team communication, decrease stigma, and facilitate care transitioning and long-term planning.
AMA J Ethics. 2020;22(8):E664-667. doi:
10.1001/amajethics.2020.664.
Kyle B. Brothers, MD, PhD and Esther E. Knapp, MD, MBE
Direct-to-consumer genetic testing requires that physicians share decision making with patients, not order unnecessary tests or interventions, and refer to genetic specialists when necessary.
AMA J Ethics. 2018;20(9):E812-818. doi:
10.1001/amajethics.2018.812.
Mandatory genetic testing of health care professionals could help structure health care organizations’ responses to a pandemic. Patients and more susceptible employees can benefit, and these benefits must be weighed against concerns about fairness, autonomy, genetic privacy, and potential loss of employment opportunities.
AMA J Ethics. 2018;20(9):E819-825. doi:
10.1001/amajethics.2018.819.
This commentary explores legal, ethical, and practical considerations for pharmacists and prescribers working together to address uncertainty in drug prescribing.
AMA J Ethics. 2021;23(6):E471-479. doi:
10.1001/amajethics.2021.471.